Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea

Abstract

AbstractViral respiratory diseases (VRDs) cause lung inflammation and inflammatory cytokine production. We study whether dapsone is responsible for its observed preventive treatment effects of the sustained viral RNA interferon response. Around 2008 and 2012, Korea’s Dementia Management Act stipulated drastic changes in the administration of dementia medication by medical staff. Participants were randomized and we compared leprosy patients with VRDs after prescribing dapsone as a standard treatment from 2005 to 2019. Significance was evaluated based on the dapsone-prescribed (+) subgroup and the dapsone-unprescribed (−) subgroup of the VRD diagnosed (+) and VRD undiagnosed (−) subgroup. We analyzed VRD ( +)/(− with dapsone (+)/(−) group and used a T-test, and designed the equation of acetylation with dapsone and acetylcholine (AA) equation. The 6394 VRD participants who received the dapsone intervention compared to the 3255 VRD participants in the control group demonstrated at T2 VRD (+) dapsone (−) (mean (M) = 224.80, SD = 97.50): T3 VRD (−) dapsone (+) (M = 110.87, SD = 103.80), proving that VRD is low when dapsone is taken and high when it is not taken. Thetvalue is 3.10, and thepvalue is 0.004395 (significant atp < 0.05). After an increase in VRDs peaked in 2009, bronchitis, COPD, and pneumonia surged in 2013. The AA equation was strongly negatively correlated with the prevalence of bronchitis and chronic obstructive pulmonary disease (COPD): with bronchitis,r(15) =  −0.823189,p = 0.005519, and with COPD,r(15) =  −0.8161,p = 0.000207 (significant atp < 0.05). Dapsone treated both bronchitis and COPD. This study provides theoretical clinical data to limit acetylcholine excess during the VRD pandemic for bronchitis, COPD, and pneumonia.